• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Indonesia·Healthcare·LABS.JK
Share

UBC Medical Indonesia Tbk. Stocks

IDR 173Last Updated 18.09.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

IDR 41.24M

IDR 173
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

UBC Medical Indonesia Tbk (LABS.JK) serves as a key supplier of medical devices throughout Indonesia. The company's operations are structured into two primary divisions: Medical Disposables and Consumables, and Diagnostics and Equipment. Its comprehensive product lineup includes advanced solutions for next-generation molecular analysis, AI-driven retina diagnostics, infectious disease detection, HPV DNA testing, real-time PCR technology, TB management systems, and newborn screening. Established in 2014, UBC Medical Indonesia Tbk is headquartered in Jakarta Timur, Jakarta, and operates as a subsidiary under the ownership of PT Optel Investama Mulia.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

22.09.2026 14:12

Morgan Stanley has updated its list of the top 15 stocks for the year. Last year's picks outperformed the S&P 500.

22.09.2026 13:48

Burry bet on copper for AI. Why did he buy shares in the little-known company Ero?

22.09.2026 12:25

Oninvest Index: Small-cap data center stocks rose 48%. What will drive this growth?

22.09.2026 12:03

Alibaba has unveiled "China's most powerful AI chip." Is this a threat to Nvidia?

22.09.2026 11:23

The creator of Zuckerberg's favorite smart rings plans to go public with a valuation of $15.6 billion

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026